EP2285858A1 - Revêtements hydrophiles à base de polyuréthanne - Google Patents

Revêtements hydrophiles à base de polyuréthanne

Info

Publication number
EP2285858A1
EP2285858A1 EP09753633A EP09753633A EP2285858A1 EP 2285858 A1 EP2285858 A1 EP 2285858A1 EP 09753633 A EP09753633 A EP 09753633A EP 09753633 A EP09753633 A EP 09753633A EP 2285858 A1 EP2285858 A1 EP 2285858A1
Authority
EP
European Patent Office
Prior art keywords
use according
mol
coating
polyurethaneurea
polycarbonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09753633A
Other languages
German (de)
English (en)
Inventor
Jürgen Köcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covestro Deutschland AG
Original Assignee
Bayer MaterialScience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer MaterialScience AG filed Critical Bayer MaterialScience AG
Publication of EP2285858A1 publication Critical patent/EP2285858A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/44—Polycarbonates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/0838—Manufacture of polymers in the presence of non-reactive compounds
    • C08G18/0842—Manufacture of polymers in the presence of non-reactive compounds in the presence of liquid diluents
    • C08G18/0847—Manufacture of polymers in the presence of non-reactive compounds in the presence of liquid diluents in the presence of solvents for the polymers
    • C08G18/0852—Manufacture of polymers in the presence of non-reactive compounds in the presence of liquid diluents in the presence of solvents for the polymers the solvents being organic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C08G18/12—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/2805—Compounds having only one group containing active hydrogen
    • C08G18/2815—Monohydroxy compounds
    • C08G18/283—Compounds containing ether groups, e.g. oxyalkylated monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
    • C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
    • C08G18/6633—Compounds of group C08G18/42
    • C08G18/6637—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38
    • C08G18/664—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/721—Two or more polyisocyanates not provided for in one single group C08G18/73 - C08G18/80
    • C08G18/722—Combination of two or more aliphatic and/or cycloaliphatic polyisocyanates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
    • C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
    • C08G18/751—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring
    • C08G18/752—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group
    • C08G18/753—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group
    • C08G18/755—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group and at least one isocyanate or isothiocyanate group linked to a secondary carbon atom of the cycloaliphatic ring, e.g. isophorone diisocyanate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
    • C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
    • C08G18/758—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing two or more cycloaliphatic rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/80—Masked polyisocyanates
    • C08G18/8061—Masked polyisocyanates masked with compounds having only one group containing active hydrogen
    • C08G18/8064—Masked polyisocyanates masked with compounds having only one group containing active hydrogen with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
    • C09D175/04—Polyurethanes

Definitions

  • the present invention relates to the use of a coating composition in the form of a polyurethane dispersion for the production of hydrophilic coatings, in particular the use of the coating composition for coating devices, in particular medical devices.
  • the hydrophilic coating materials according to the invention are also applicable to the protection of surfaces from fogging, for the production of easy-to-clean or self-cleaning surfaces and to reduce the dirt absorption of these surfaces.
  • the hydrophilic coating materials of the invention are also capable of reducing or avoiding the formation of water spots on surfaces.
  • hydrophilic surfaces can be produced with the polyurethane solutions according to the invention, which are no longer grown to a significant extent by organisms living in the water (antifouling properties).
  • Further fields of application of these coating materials according to the invention are applications in the printing industry, for cosmetic formulations as well as for systems also outside of medical technology applications which release active ingredients.
  • the use of medical devices can be greatly improved by the equipment with hydrophilic surfaces.
  • the insertion and displacement of urine or blood vessel catheters is made easier by the fact that hydrophilic surfaces in contact with blood or urine adsorb a water film.
  • the friction of the catheter surface is reduced compared to the vessel walls, so that the catheter is easier to use and move.
  • a direct washing of the equipment before the intervention can be made to reduce the friction by forming a homogeneous Wasserf ⁇ lms. Affected patients have less pain and the risk of injury to the vessel walls is thereby reduced.
  • the use of catheters always involves the risk of blood clots forming.
  • hydrophilic coatings are generally considered helpful for antithrombogenic coatings.
  • Polyurethane coatings which are prepared starting from solutions or dispersions of corresponding polyurethanes, are fundamentally suitable for the production of corresponding surfaces.
  • US Pat. No. 5,589,563 describes the use of surface-modified end-group coatings for polymers used in the field of biomedicine, which can also be used for coating medical devices.
  • the resulting coatings are prepared from solutions or dispersions and the polymeric coatings comprise various end groups selected from amines, fluorinated alkanols, polydimethylsiloxanes and amine-terminated polyethylene oxides.
  • these polymers have a coating for medical devices no satisfactory properties, especially with regard to the required hydrophilicity on.
  • a disadvantage of aqueous dispersions, as described, inter alia, in US Pat. No. 5,589,563, is, moreover, that the size of the dispersed particles makes the coatings relatively rough.
  • the resulting coatings of aqueous dispersions are generally not sufficiently stable. Therefore, there is a need for hydrophilic coating systems which have excellent hydrophilicity and at the same time a relatively smooth surface and high stability.
  • Polyurethane solutions per se are known from the prior art, but have not been used for coating medical devices, with the exception of the already mentioned polyurethane solutions according to US Pat. No. 5,589,563.
  • DE-A 22 21 798 describes a process for the preparation of stable and light-stable solutions of polyurethane ureas from prepolymers having terminal isocyanate groups and diamines in low-polar solvents, where prepolymers of a) substantially linear polyhydroxyl compounds having molecular weights of about 500 to 5000, b) optionally low molecular weight dihydroxy compounds and c) aliphatic or cycloaliphatic diisocyanates, wherein the molar ratio of hydroxyl and isocyanate groups between about 1: 1.5 and 1: 5, in a solvent (mixture) of optionally chlorinated aromatic and / or chlorinated aliphatic hydrocarbons and primary, secondary and / or tertiary aliphatic and / or cycloaliphatic alcohols with diamines as Kettenver longer be reacted, wherein at least 80 mol% of the chain extender 1,4-diamino-cyclohexane with a cis / trans
  • DE-A 22 52 280 describes a process for coating textile substrates by the reversal process with adhesive and topcoats from solutions of aliphatic, segmented polyurethane elastomers which are polycarbonate-containing.
  • EP-A 0 125 466 describes a process for the multi-coat reverse coating of textile, preferably sheet-like, bases for the production of synthetic leather from at least one top coat solution and at least one adhesion coat solution based on polyurethanes. None of these documents describes a hydrophilic polyurethane resin solution which is used for coating purposes of medical devices and meets the previously defined requirements.
  • compositions which are suitable for the coating of medical devices having hydrophilic surfaces Since these surfaces are often used in blood contact, the surfaces of these materials should also have good blood compatibility and in particular reduce the risk of the formation of blood clots. Furthermore, the resulting coatings should be smooth and have high stability.
  • the subject of this invention are coating compositions in the form of specific polyurethane solutions.
  • the polyurethane solutions to be used according to the invention comprise at least one polyurethaneurea which is terminated with a copolymer unit of polyethylene oxide and polypropylene oxide.
  • compositions of these particular polyurethaneureas in solutions are eminently suitable for the production of coatings on medical devices, provide them with an outstanding hydrophilic coating, form smooth surfaces, have high stability and at the same time the risk of formation of blood clots during treatment reduce with the medical device.
  • Polyurethane ureas in the context of the present invention are polymeric compounds which
  • the coating compositions in the form of a solution to be used according to the invention are based on polyurethane adhesives which have essentially no ionic have modification.
  • polyurethane adhesives which have essentially no ionic have modification.
  • this is understood to mean that the polyurethaneureas to be used according to the invention have essentially no ionic groups, in particular no sulfonate, carboxylate, phosphate and phosphonate groups.
  • the term "essentially no ionic groups” is understood to mean that the resulting coating of the polyurethaneurea has ionic groups with a proportion of generally not more than 2.50% by weight, in particular not more than 2.00% by weight.
  • the polyurethaneurea no ionic groups are preferably carboxylates.
  • the coating compositions in the form of solutions used in the invention include polyurethanes, which are preferably substantially linear molecules but may also be branched.
  • substantially linear molecules are readily cross-linked systems which contain a polyol component having an average hydroxyl functionality of preferably 1.7 to 2.3, in particular 1.8 to 2.2, particularly preferably 1.9 to 2.1.
  • the number-average molecular weight of the polyurethane ureas preferably used according to the invention is preferably from 1000 to 200,000, more preferably from 5,000 to 100,000.
  • the number-average molecular weight is measured as the standard in dimethylacetamide at 30 ° C. against polystyrene.
  • the coating systems based on polyurethane ureas to be used according to the invention are described in more detail below.
  • the polyurethane-containing coating compositions according to the invention in the form of a solution are prepared by reacting synthesis components which comprise at least one polycarbonate polyol component, at least one polyisocyanate component, at least one polyoxyalkylene ether component, at least one diamine and / or aminoalcohol component and optionally one further polyol component.
  • the polyurethaneurea-based coating composition of the invention in the form of a solution has units derived from at least one hydroxyl-containing polycarbonate.
  • suitable for introducing units based on a hydroxyl-containing polycarbonate are polyhydroxy compounds having an average hydroxyl functionality of 1.7 to 2.3, preferably from 1.8 to 2.2, particularly preferably from 1.9 to 2.1.
  • hydroxyl-containing polycarbonates are polycarbonates of OHZahl specific molecular weight of preferably 400 to 6000 g / mol, more preferably 500 to 5000 g / mol, in particular from 600 to 3000 g / mol in question, for example, by reaction of carbonic acid derivatives, such as diphenyl carbonate, Dimethyl carbonate or phosgene, with polyols, preferably diols, are available.
  • diols examples include ethylene glycol, 1,2- and 1,3-propanediol, 1,3- and 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, neopentyl glycol, 1,4-bishydroxymethylcyclohexane , 2-methyl-l, 3-propanediol, 2,2,4-trimethylpentane-l, 3-diol, di-, tri- or tetraethylene glycol, dipropylene glycol, polypropylene glycols, dibutylene glycol, polybutylene glycols, bisphenol A, tetrabromobisphenol A but also lactone-modified diols in question.
  • the diol component contains from 40 to 100% by weight of hexanediol, preferably 1,6-hexanediol and / or hexanediol derivatives, preferably those which have, in addition to terminal OH groups, ether or ester groups, e.g. Products obtained by reacting 1 mole of hexanediol with at least 1 mole, preferably 1 to 2 moles of caprolactone or by etherification of hexanediol with itself to di- or Trihexylenglykol. Polyether-polycarbonate diols can also be used. The hydroxyl polycarbonates should be substantially linear.
  • polyfunctional components in particular low molecular weight polyols.
  • Glycerol, trimethylolpropane, hexanetriol-1,2,6, butanetriol-1,2,4, trimethylolpropane, pentaerythritol, quinitol, mannitol, sorbitol, methyl glycoside or 1,3,4,6-dianhydrohexitols are suitable for this purpose, for example.
  • Further preferred polycarbonate diols are those based on mixtures of 1,6-hexanediol and 1,4-butanediol.
  • the polycarbonate is preferably formed substantially linear and has only a slight three-dimensional cross-linking, so that polyurethanes are formed, which have the aforementioned specification.
  • the polyurethaneurea-based coating composition according to the invention has units which are based on at least one polyisocyanate as the synthesis component.
  • polyisocyanates (b) it is possible to use all aromatic, araliphatic, aliphatic and cycloaliphatic isocyanates known to those skilled in the art having an average NCO functionality> 1, preferably> 2, individually or in any mixtures with one another, it being immaterial whether these are or phosgene-free processes.
  • polyisocyanates can be used individually or in any mixtures with one another.
  • Isocyanates from the series of aliphatic or cycloaliphatic representatives are preferably used, these having a carbon skeleton (without the NCO groups contained) of 3 to 30, preferably 4 to 20 carbon atoms.
  • Particularly preferred compounds of component (b) correspond to the abovementioned type with aliphatically and / or cycloaliphatically bonded NCO groups such as, for example, bis (isocyanatoalkyl) ether, bis- and tris (isocyanatoalkyl) benzenes, - toluene, and also -xylols, propane diisocyanates , Butane diisocyanates, pentane diisocyanates, hexane diisocyanates (eg hexamethylene diisocyanate, HDI), heptane diisocyanates, octane diisocyanates, nonane diisocyanates (eg trimethyl-HDI (TMDI) generally as a mixture of 2,4,4- and 2,2,4-isomers ), Nonanetriisocyanates (eg 4-isocyanatomethyl-l, 8-octanediisocyanate), de
  • Very particularly preferred compounds of component (b) are hexamethylene diisocyanate (HDI), trimethyl-HDI (TMDI), 2-methylpentane-l, 5-diisocyanate (MPDI), isophorone diisocyanate (EPDI), 1,3- and 1,4 Bis (isocyanatomethyl) cyclohexane (H 6 XDI), bis (isocyanatomethyl) norbornane (NBDI), 3 (4) isocyanatomethyl-1-methylcyclohexyl isocyanate (IMCI) and / or 4,4'-bis (isocyanatocyclohexyl ) methane (H 12 MDI) or mixtures of these isocyanates.
  • HDI hexamethylene diisocyanate
  • TMDI trimethyl-HDI
  • MPDI 2-methylpentane-l
  • EPDI isophorone diisocyanate
  • H 6 XDI 1,3- and 1,4 Bis (iso
  • the amount of component (b) in the coating composition to be used in the present invention is preferably 1.0 to 3.5 mol, more preferably 1.0 to 3.3 mol, in particular 1.0 to 3.0 mol, in each case based on the component (a) of the coating composition to be used according to the invention.
  • Nonionically hydrophilicizing compounds (c) are, for example, monovalent polyalkylene oxide polyether alcohols having a statistical average of 5 to 70, preferably 7 to 55, ethylene oxide units per molecule, as are obtainable in a conventional manner by alkoxylation of suitable starter molecules (eg in Ullmanns Enzyklopadie der ischen Chemie 4th Edition, Volume 19, Verlag Chemie, Weinheim pp.
  • starter molecules are saturated monoalcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol, the isomers pentanols, hexanols, octanols and nonanols, n-decanol, n-dodecanol, n-tetradecanol, n Hexadecanol, n-octadecanol, cyclohexanol, the isomeric methylcyclohexanols or hydroxymethylcyclohexane, 3-ethyl-3-hydroxymethyloxetane or tetrahydrofurfuryl alcohol, diethylene glycol monoalkyl ethers, such as, for example, diethylene glycol monobutyl ether, unsaturated alcohols, such as allyl alcohol, 1,1-di
  • alkylene oxides ethylene oxide and propylene oxide can be used in any order or even as a mixture in the alkoxylation reaction.
  • the polyalkylene oxide polyether alcohols are mixed polyalkylene oxide polyethers of ethylene oxide and propylene oxide, the alkylene oxide units of which preferably consist of at least 30 mol%, particularly preferably at least 40 mol%, of ethylene oxide units.
  • Preferred nonionic compounds are monofunctional mixed polyalkylene oxide polyethers which have at least 40 mol% of ethylene oxide and not more than 60 mol% of propylene oxide units.
  • the average molecular weight of the polyoxyalkylene ether is preferably 500 g / mol to 5000 g / mol, particularly preferably 1000 g / mol to 4000 g / mol, in particular 1000 to 3000 g / mol.
  • the amount of component (c) in the coating composition to be used according to the invention is preferably from 0.01 to 0.5 mol, particularly preferably from 0.02 to 0.4 mol, in particular from 0.04 to 0.3 mol, in each case based on the component (a) of the coating composition to be used according to the invention.
  • the polyurethaneureas having terminal groups based on mixed polyoxyalkylene ethers of polyethylene oxide and polypropylene oxide are particularly suitable for producing coatings having a high hydrophilicity.
  • the coatings according to the invention have a markedly low contact angle and are therefore more hydrophilic.
  • the polyurethaneurea solution according to the invention has units which are based on at least one diamine or an amino alcohol as the synthesis component and serve as so-called chain extenders (d).
  • chain extenders include di- or polyamines and hydrazides, for example hydrazine, ethylenediamine, 1,2- and 1,3-diaminopropane, 1, 4-diaminobutane, 1,6-diaminohexane, isophoronediamine, isomer mixture of 2,2,4- and 2,4,4-trimethyl-hexamethylenediamine, 2-methylpentamethylenediamine, diethylenetriamine, 1,3- and 1,4-xylylenediamine, ⁇ , ⁇ , ⁇ ', ⁇ '-tetramethyl-l, 3- and 1,4-xylylenediamine and 4,4'-diamino-dicyclohexylmethane, dimethylethylenediamine, hydrazine, adipic dihydr
  • tetraalkyldicyclohexylmethanes e.g. 4,4'-diamino-3,5-diethyl-3 ', 5'-diisopropyldicyclohexylmethane.
  • diamines or amino alcohols are generally suitable low molecular weight diamines or amino alcohols containing active hydrogen with respect to NCO groups of different reactivity, such as compounds containing not only a primary amino group but also secondary amino groups or in addition to an amino group (primary or secondary) and OH groups exhibit.
  • Examples of these are primary and secondary amines, such as 3-amino-1-methylaminopropane, 3-amino-1-ethylaminopropane, 3-amino-1-cyclohexylaminopropane, 3-amino-1-methylaminobutane, furthermore amino alcohols, such as N-aminoethylethanolamine, ethanolamine , 3-aminopropanol, neopentanolamine and more preferably diethanolamine.
  • the component (d) of the coating composition to be used according to the invention can be used as a chain extender in their preparation.
  • the amount of constituent (d) in the solution according to the invention of the coating composition is preferably 0.1 to 1.5 mol, more preferably 0.2 to 1.3 mol, in particular 0.3 to 1.2 mol, in each case based on the component (a) of the coating composition to be used according to the invention.
  • the coating composition according to the invention which is in the form of a solution comprises additional units which are based on at least one further polyol as the synthesis component.
  • the other low molecular weight polyols (e) used to build up the polyurethane ureas generally cause stiffening and / or branching of the polymer chain.
  • the molecular weight is preferably 62 to 500 g / mol, particularly preferably 62 to 400 g / mol, in particular 62 to 200 g / mol.
  • Suitable polyols may contain aliphatic, alicyclic or aromatic groups. Mentioned here are, for example, the low molecular weight polyols having up to about 20 carbon atoms per molecule, such as.
  • ester diols such as e.g. ⁇ -Hydroxybutyl- ⁇ -hydroxy-caproic acid esters, ⁇ -hydroxyhexyl- ⁇ -hydroxybutyric acid esters, adipic acid ( ⁇ -hydroxyethyl) esters or terephthalic acid bis ( ⁇ -hydroxyethyl) esters may be used.
  • the amount of component (e) in the coating composition to be used in the present invention is preferably 0.05 to 1.0 mol, more preferably 0.05 to 0.5 mol, especially 0.1 to 0.5 mol, in each case based on the constituent (a) the coating composition to be used in the invention.
  • the reaction of the isocyanate-containing component (b) with the hydroxy- or amine-functional compounds (a), (c), (d) and optionally (e) is usually carried out while maintaining a slight excess of NCO over the reactive hydroxy or amine compounds.
  • a target viscosity remains of active isocyanate remain.
  • residues must be blocked so that it does not react with large polymer chains.
  • Such a reaction leads to the three-dimensional networking and gelling of the approach.
  • the processing of such a coating solution is no longer possible.
  • the approaches contain high levels of alcohols. These alcohols block the remaining isocyanate groups within several hours of standing or stirring the mixture at room temperature.
  • the polyurethaneurea coating compositions provided according to the invention in the form of a solution can also contain monomers (f) as structural components, which are located at the chain ends and close them.
  • These structural components are derived, on the one hand, from monofunctional compounds reactive with NCO groups, such as monoamines, in particular mono-secondary amines or monoalcohols.
  • monoamines such as monoamines, in particular mono-secondary amines or monoalcohols.
  • monoamines such as monoamines, in particular mono-secondary amines or monoalcohols.
  • examples include ethanol, n-butanol, ethylene glycol monobutyl ether, 2-ethylhexanol, 1-octanol, 1-dodecanol, 1-hexadecan-ol, methylamine, ethylamine, propylamine, butylamine, octylamine, laurylamine, stearylamine, isononyloxypropylamine, Dimethylamine, diethylamine, dipropylamine, dibutylamine, N-methylaminopropylamine, diethyl (methyl) aminoprop
  • the building blocks (f) are essentially used in the coating composition of the invention in the form of a solution to destroy the NCO excess, the required amount depends essentially on the amount of NCO excess and can not be specified in general ,
  • Unreacted isocyanate is preferably converted into terminal urethanes by the solvent alcohols present in very large concentrations.
  • inventively provided solutions of the polyurethaneurea coating composition may moreover contain further constituents and additives customary for the intended purpose.
  • additional constituents and additives customary for the intended purpose.
  • pharmacologically active substances pharmaceuticals and additives which promote the release of pharmacologically active substances ("drug-eluting additives").
  • Pharmacological active ingredients or medicaments which can be used in the coatings according to the invention on the medical devices and can therefore be contained in the solutions according to the invention are, for example, thrombore-resistant agents, antibiotic agents, antitumor agents, growth hormones, antiviral agents, antiangiogenic agents, angiogenic agents Means, antimitotic, anti-inflammatory de means, cell cycle regulating agents, genetic agents, hormones, and their homologues, derivatives, fragments, pharmaceutical salts and combinations thereof.
  • pharmacologically active agents or drugs therefore include thromboresistant (non-thrombogenic) agents or other agents for suppressing acute thrombosis, stenosis or late re-stenosis of the arteries, for example heparin, streptokinase, urokinase, tissue plasminogen activator, Anti-thromboxane B 2 agents; Anti-B-thromboglobulin, prostaglandin-E, aspirin, dipyridol, anti-thromboxane A 2 agents, murine monoclonal antibody 7E3, triazolopyrimidine, ciprosten, hirudin, ticlopidine, nicorandil, etc.
  • a growth factor may also be considered as a Medicaments can be used to suppress intimal fibromuscular hyperplasia at the arterial stenosis site, or any other inhibitor of cell growth at the stenosis site can be used.
  • the pharmacological agent or drug may also consist of a vasodilator to counteract vasospasm, for example an antispasmodic agent such as papaverine.
  • the drug may be a vasoactive agent per se, such as calcium antagonists, or ⁇ - and ⁇ -adrenergic agonists or antagonists.
  • the therapeutic agent may be a biological adhesive such as medical grade cyanoacrylate or fibrin used, for example, for adhering a tissue valve to the wall of a coronary artery.
  • the therapeutic agent may also be an antineoplastic agent such as 5-fluorouracil, preferably with a controlling releasing carrier for the agent (e.g., for the application of a sustained controlled release anti-neoplastic agent at a tumor site).
  • the therapeutic agent may be an antibiotic, preferably in combination with a sustained release, controlling releasing carrier, from the coating of a medical device to a localized source of infection within the body.
  • the therapeutic agent may contain steroids for the purpose of suppressing inflammation in localized tissue or for other reasons.
  • suitable drugs include:
  • antibiotic agents such as penicillins, cephalosprins, vacomycins, aminoglycosides, quinolones, polymxins, erythromycins; Tertracyclines, chloramphenicols, clindamycins, lincomycins, sulfonamides, their homologues, analogues, derivatives, pharmaceutical salts and mixtures thereof;
  • paclitaxel, docetaxel, immunosuppressants such as sirolimus or everolimus, alkylating agents including mechlorethamine, chlorambucil, cycl
  • Daunomycin, bleomycin and mitomycin Nitrosurea including carmustine and lomustine; inorganic ions including cisplatin; biological reaction modifiers including interferon; angiostatic and endostatic agents; Enzymes including asparaginase; and hormones include tamoxifen and flutamide, their homologues, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof;
  • antiviral agents such as amantadine, rimantadine, rabavirin, idoxuridine, vidarabine, trifluridine, acyclovir, ganciclocir, zidovudine, phosphonoformates, interferons, their homologues, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof; and e) anti-inflammatory agents such as ibuprofen, dexamethasone or methylprednisolone.
  • the coating composition to be used according to the invention in the form of a solution comprises a polyurethaneurea which is at least built up from a) at least one polycarbonate polyol; b) at least one polyisocyanate; c) at least one monofunctional polyoxyalkylene ether; d) at least one diamine or an aminoalcohol.
  • the coating composition to be used according to the invention in the form of a solution comprises a polyurethaneurea which is at least built up from a) at least one polycarbonate polyol; b) at least one polyisocyanate; c) at least one monofunctional polyoxyalkylene ether; d) at least one diamine or an aminoalcohol; and e) at least one polyol.
  • the coating composition to be used according to the invention in the form of a solution comprises a polyurethaneurea which is at least built up a) at least one polycarbonate polyol; b) at least one polyisocyanate; c) at least one monofunctional polyoxyalkylene ether; d) at least one diamine or an aminoalcohol; e) at least one polyol; f) at least one further amine- and / or hydroxy-containing building block.
  • the coating compositions in the form of solutions to be used according to the invention preferably comprise polyurethane ureas which are at least synthesized from a) at least one polycarbonate polyol having an average molecular weight between 400 g / mol and 6000 g / mol and a hydroxyl functionality of 1.7 to 2.3 or from mixtures of such polycarbonate polyols; b) at least one aliphatic, cycloaliphatic or aromatic polyisocyanate or mixtures of such polyisocyanates in an amount per mole of the polycarbonate polyol from 1.0 to 3.5 mol; c) at least one monofunctional polyoxyalkylene ether or a mixture of such polyethers having an average molecular weight between 500 g / mol and 5000 g / mol in an amount per mole of the polycarbonate polyol of 0.01 to 0.5 mol; d) at least one aliphatic or cycloaliphatic diamine or at least one aminoalcohol as
  • the coating composition in the form of a solution to polyurethaneureas which are at least synthesized from a) at least one polycarbonate polyol having an average molecular weight between 500 g / mol and 5000 g / mol and a hydroxyl functionality of 1.8 to 2.2 or mixtures of such polycarbonate polyols; b) at least one aliphatic, cycloaliphatic or aromatic polyisocyanate or mixtures of such polyisocyanates in an amount of from 1.0 to 3.3 mol per mole of the polycarbonate polyol; c) at least one monofunctional polyoxyalkylene ether or a mixture of such polyethers having an average molecular weight between 1000 g / mol and 4000 g / mol in an amount per mole of the polycarbonate polyol of 0.02 to 0.4 mol; d) at least one aliphatic or cycloaliphatic diamine or at least one aminoalcohol as
  • polyurethane ureas in the coating solution which are at least synthesized are preferably composed of a) at least one polycarbonate polyol having an average molecular weight between 600 g / mol and 3000 g / mol and a hydroxyl functionality of 1.9 to 2.1 or from Mixtures of such polycarbonate polyols; b) at least one aliphatic, cycloaliphatic or aromatic polyisocyanate or mixtures of such polyisocyanates in an amount of from 1.0 to 3.0 mol per mole of the polycarbonate polyol; c) at least one monofunctional polyoxyalkylene ether or a mixture of such polyethers having an average molecular weight between 1000 g / mol and 3000 g / mol in an amount per mole of the polycarbonate polyol of 0.04 to 0.3 mol, wherein a mixture of polyethylene oxide and polypropylene oxide in particular is preferred; and d) at least one aliphatic or cycl
  • the coating compositions to be used according to the invention may comprise the antifouling agents known from the prior art. Their presence usually enhances the already excellent antifouling properties of the surfaces produced by the coating compositions according to the invention.
  • a coating composition in the form of a solution to be used according to the invention can be used to form a coating on a medical device.
  • medical device is to be broadly understood in the context of the present invention
  • suitable, non-limiting examples of medical devices include contact lenses, cannulas, catheters, for example, urological catheters such as bladder catheters or ureteral catheters, central venous catheters, venous catheters, or Inlet and outlet catheters; dilation balloons, catheters for angioplasty and biopsy, catheters used for insertion of a stent, a graft or a kavafilter, balloon catheters or other expandable medical devices, endoscopes, larnygoscopes, tracheal devices such as endotracheal hoses, respirators and other tracheal suction devices, bronchoalveolar irrigation catheters, catheters used in coronary angioplasty, guide rods, introducers and the like, vascular grafts, pacemaker parts, cochlear implants, dental implant tubes for feeding, Dr nage hoses and guidewires.
  • urological catheters such as bladder catheters or ureter
  • the coating solutions to be used according to the invention can be used for the production of protective coatings, for example for gloves, stents and other implants, extracorporeal blood tubes (tubes), membranes, for dialysis, for example, blood filters, circulatory assist devices, bandage materials the wound care, urine bag and ostomy pouch are used.
  • implants containing a medically effective agent such as medicated stents or balloon surfaces or contraceptive devices.
  • the medical device is formed from catheters, endoscopes, laryngoscopes, endotracheal tubes, feeding tubes, guide rods, stents, and other implants.
  • medical devices with very hydrophilic and thus lubricious, blood-compatible surfaces can be produced by using aqueous, nonionically stabilized polyurethane dispersions of the type described above for coating the medical devices.
  • the coating compositions described above are preferably obtained as an organic solution and applied to the surface of the medical devices.
  • the coating compositions described above can also be used for other non-medical technical applications.
  • Substrates for applications outside medical coatings are, for example, metals, plastics, ceramics, textiles, leather, wood, paper, painted surfaces of all substrates mentioned and glasses.
  • the coating materials can be applied directly to the substrate or alternatively to a previously applied to the substrate primer.
  • the coatings produced according to the invention serve as protection of surfaces from fogging with moisture, for the production of easy-to-clean or self-cleaning surfaces. These hydrophilic coatings also reduce the absorption of dirt and prevent the formation of water spots.
  • Conceivable outdoor applications are, for example, window panes and skylights, glass facades or Plexiglas roofs. In the interior, such materials can be used for the coating of surfaces in the sanitary area.
  • Other applications include the coating of optical glasses and lenses such as eyeglass lenses, binocular eyepiece and lens lenses, and lens lenses for cameras or packaging materials such as food packaging to prevent moisture fogging or condensed water drop formation.
  • the coating materials to be used according to the invention are also suitable for finishing surfaces in contact with water to reduce the growth.
  • This effect is also called antifouling effect.
  • a very important application of this antifouling effect is in the area of underwater painting of ship hulls.
  • Ship hulls without anti-fouling equipment are very quickly overgrown by marine organisms, which leads to a reduction of the possible speed and a higher fuel consumption due to increased friction.
  • the coating materials according to the invention reduce or prevent the growth of marine organisms and prevent the above-described disadvantages of this growth.
  • Further applications in the field of antifouling coatings are articles for fishing such as fishing nets and all metallic substrates in underwater use such as pipelines, oil rigs, lock chambers and gates etc.
  • Hulls which have surfaces produced with the coating materials according to the invention, in particular below the waterline also have one reduced frictional resistance, so that such equipped ships either have a reduced fuel consumption or reach higher speeds. This is particularly interesting in the sport boat area and yacht building.
  • hydrophilic coating materials are hydrophilized and are characterized printable with polar inks or can be applied by means of inkjet technology.
  • hydrophilic coatings according to the invention are formulations for cosmetic applications.
  • Active substance-releasing systems based on the hydrophilic coating materials according to the invention are also conceivable outside medical technology, for example for applications in crop protection as carrier material for active ingredients.
  • the entire coating can then be regarded as an active substance-releasing ssystem and be used, for example, for coating seed (seed grains). Due to the hydrophilic properties of the coating, the active ingredient contained in the moist soil can escape and develop its intended effect without the germination of the seed is impaired.
  • the coating agent safely binds the active substance to the seed, so that, for example, when the seed is injected into the soil with the spreading machine, the active substance is not detached, as a result of which it produces undesired effects, e.g. could develop on the existing fauna (bee endangerment by insecticides, which are supposed to prevent the insect infestation of the seed in the soil).
  • coating solutions are preferred which are composed of a mixture of polycarbonate polyols and a monofunctional polypropylene oxide-polyethylene oxide alcohol.
  • the coatings of the medical devices are prepared starting from solutions of the coating composition described in more detail above.
  • the resulting coatings differ on medical devices, depending on whether the coating composition described above is prepared from a dispersion or a solution.
  • the coatings according to the invention have advantages on medical devices if they are obtained starting from solutions of the above-described coating compositions.
  • the medical devices according to the invention can be coated by means of various methods with the hydrophilic polyurethane solutions. Suitable coating techniques include, for example, doctoring, printing, transfer coating, spraying, spin coating or dipping.
  • the organic polyurethane solutions can be prepared by any method.
  • the reaction takes place at a temperature of preferably between 60 and 110 0 C, particularly preferably 75 to 110 ° C, particularly 90 to 110 ° C, with temperatures of 110 ° C is preferred because of the speed of the reaction. Higher temperatures can also be used, but there is a risk in individual cases and depending on the individual components used that decomposition processes and discoloration occur in the resulting polymer.
  • the reaction in melt is preferred, but there is a risk that it comes to high viscosities of the reacted mixtures. In these cases, it is also advisable to add solvents. However, it should preferably not contain more than about 50 wt .-% of solvent, otherwise the dilution significantly slows down the reaction rate.
  • reaction in the melt can take place in a period of 1 hour to 24 hours.
  • Low addition of solvent leads to a slowdown, but the reaction periods are within the same time periods.
  • the order of addition or conversion of the individual constituents may differ from the sequence indicated above. This may be particularly advantageous if the mechanical properties of the resulting coatings to be changed. If, for example, all hydroxyl-containing components are reacted simultaneously, a mixture of hard and soft segments is formed. For example, if the low molecular weight polyol is selected after the polycarbonate-polyol component te gives, you get defined blocks, which can bring other properties of the resulting coatings with it. Thus, the present invention is not limited to any order of addition or reaction of the individual components of the polyurethane coating. Then, further solvent is added and the optionally dissolved chain extender diamine or the dissolved chain extender amino alcohol (synthesis component (d)) is added.
  • the further addition of the solvent is preferably carried out stepwise, so as not to slow down the reaction unnecessarily, which would happen if the amount of solvent were completely added, for example at the beginning of the reaction. Furthermore, it is bound at a high content of solvent at the beginning of the reaction at a relatively low temperature, which is at least co-determined by the nature of the solvent. This also leads to a slowing of the reaction.
  • the remaining residues of NCO can be blocked by a mono-functional aliphatic amine.
  • the remaining isocyanate groups are preferably blocked by reaction with the alcohols contained in the solvent mixture.
  • Suitable solvents for the preparation and use of the polyurethaneurea solutions according to the invention are all conceivable solvents and solvent mixtures such as dimethylformamide, N-methylacetamide, tetramethylurea, N-methylpyrrolidone, aromatic solvents such as toluene, linear and cyclic esters, ethers, ketones and Alcohols in question.
  • esters and ketones are, for example, ethyl acetate, butyl acetate, acetone, ⁇ -butyrolactone, methyl ethyl ketone and methyl isobutyl ketone.
  • examples of the alcohols used together with the toluene are ethanol, n-propanol, iso-propanol and 1-methoxy-2-propanol.
  • the polyurethane solutions receives.
  • the solids content of the polyurethane solutions is generally between 5 to 60 wt .-%, preferably 10 to 40 wt .-%.
  • the polyurethane solutions can be diluted as desired with toluene / alcohol mixtures in order to be able to variably adjust the thickness of the coating. All concentrations of 1 to 60 wt .-% are possible, preferred are concentrations in the range 1 to 40 wt .-%.
  • any layer thicknesses can be achieved, for example, some 100 nm up to a few 100 microns, and in the context of the present invention also higher and lower thicknesses are possible.
  • Other additives such as antioxidants or pigments may also be used.
  • further additives such as handle auxiliaries, dyes, matting agents, UV stabilizers, light stabilizers, water repellents and / or leveling agents may be used. Based on these solutions, medical coatings are then prepared by the methods described above.
  • the coating of medical devices can be coated.
  • the coating of medical devices that are made of plastic or metals is preferred.
  • metals which can be mentioned are: medical stainless steel and nickel-titanium alloys.
  • Many polymer materials are conceivable from which the medical device can be constructed, for example polyamide; polystyrene; polycarbonate; polyether; Polyester; polyvinyl acetate; natural and synthetic rubbers; Block copolymers of styrene and unsaturated compounds such as ethylene, butylene and isoprene; Polyethylene or copolymers of polyethylene and polypropylene; Silicone; Polyvinyl chloride (PVC) and polyurethanes.
  • PVC Polyvinyl chloride
  • other suitable coatings can be applied as a substrate before the application of these hydrophilic coating materials.
  • the medical devices can be coated by various methods with the hydrophilic polyurethane dispersions. Suitable coating techniques are doctoring, printing, transfer coating, spraying, spin coating or dipping.
  • the layers produced according to the invention to be used coating compositions are characterized by a high blood compatibility. As a result, working with these coatings is particularly advantageous in blood contact.
  • the materials show reduced coagulation tendency in blood contact compared to prior art polymers.
  • the NCO content of the resins described in the Examples and Comparative Examples was determined by titration in accordance with DIN EN ISO 11909.
  • the solids contents were determined in accordance with DIN-EN ISO 3251. 1 g of polyurethane dispersion was dried at 115 ° C. to constant weight (15-20 min) using an infrared drier.
  • the measurement of the average particle sizes of the polyurethane dispersions is carried out using the High Performance Particle Sizer (HPPS 3.3) from Malvem Instruments.
  • Viscosity measurements were carried out with the Physics MCR 51 Rheometer from Anton Paar GmbH, Ostfildern, Germany.
  • Desmophen ® C2200 polycarbonate polyol, OH number 56 mg KOH / g, number average molecular weight 2000 g / mol (Bayer MaterialScience AG, Leverkusen, DE)
  • Desmophen ® C 1200 polycarbonate polyol, OH number 56 mg KOH / g, number average molecular weight 2000 g / mol (Bayer MaterialScience AG, Leverkusen, DE)
  • Desmophen ® XP 2613 polycarbonate polyol OH number 56 mg KOH / g, number average molecular weight 2000g / mol (Bayer Material Science AG, Leverkusen, DE)
  • PolyTHF v 2000 polytetramethylene glycol polyol, OH number 56 mg KOH / g, number average molecular weight 2000 g / mol (BASF AG, Ludwigshafen, DE)
  • the static contact angle measurements were made on 25x75 mm glass slides using a spincoater (RC5 Gyrset 5, Karl Suess, Garching, Germany). A slide was clamped on the sample plate of the spin coater and homogenously covered with about 2.5-3 g of organic 15% strength polyurethane solution. All organic polyurethane solutions were mixed with a solvent mixture of 65% by weight of toluene and 35% by weight of isopropanol to a polymer content of 15% by weight diluted. By rotating the sample tray for 20 sec at 1300 rpm, a homogeneous coating was obtained which was dried at 100 ° C for 1 h and then at 50 ° C for 24 h. The resulting coated slides were subjected directly to a contact angle measurement.
  • the polycarbonate-containing coatings of Examples 1-5 give highly hydrophilic coatings with static contact angles ⁇ 40 °.
  • the polyTHF-containing coatings 7-9 are substantially more non-polar, although the composition of these coatings are otherwise identical to those of Examples 1 and 2.
  • This comparative example describes the synthesis of a polyurethane urea polymer which, instead of the mixed monofunctional polyethylene-polypropylene oxide alcohol LB 25, contains the same molar proportion of a pure monofunctional polyethylene oxide alcohol.
  • the polymer is identical to that of Example 1 except that it contains a different terminal group.
  • the synthesis in toluene and alcohols as described in Examples 1-7 does not work when using this alcohol. Therefore, the synthesis is carried out in pure dimethylformamide (DMF).
  • DMF dimethylformamide
  • Example 8 As described in Example 8, the polyurethane solutions of Examples 9 and 10 were used to produce films on glass and to measure static contact angles.
  • Example 10 produced with the mixed (polyethylene oxide / polypropylene oxide) monofunctional polyether alcohol shows at 36 ° a significantly lower static contact angle than the film of Example 9 (55 °) which contains pure polyethylene oxide units.
  • Example 12 Synthesis of a polyurethane according to the invention in organic solution. This product was compared with the appropriately aqueous-prepared polyurethane of Example 13 (see Example 14). 277.2 g of Desmophen ® C 2200, 33.1 g LB 25, 6.7 g of neopentyl glycol, 71.3 g of 4,4'-bis (iso-cyanatocyclohexyl) methane (MDI Hi 2) and 11.9 g of isophorone diisocyanate reacted at 110 ° C to a constant NCO content of 2.4%. It was allowed to cool and diluted with 500.0 g toluene and 350.0 g iso-propanol.
  • MDI Hi 2 4,4'-bis (iso-cyanatocyclohexyl) methane
  • the finished prepolymer was dissolved at 50 ° C in 711 g of acetone and then added at 40 ° C, a solution of 4.8 g of ethylenediamine in 16 g of water within 10 min. The stirring time was 5 min. The mixture was then dispersed within 15 minutes by adding 590 g of water. This was followed by removal of the solvent by distillation in vacuo. A storage-stable polyurethane dispersion with a solids content of 40.7% and an average particle size of 136 nm was obtained. The pH of this dispersion was 6.7.
  • Example 12 The two coatings of Examples 12 and 13 were applied to release paper with a 200 ⁇ m doctor blade.
  • the coating of Example 12 was applied in undiluted form, the aqueous dispersion was added prior to film formation with 2 wt% of a thickener (Borchi Gel ® A LA, Fa. Borchers, Langenfeld, Germany) and 30 min at RT homogenized by stirring.
  • the wet films were dried at 100 ° C. for 15 minutes.
  • Tensile strength and elongation at break are measured in the dry state and after 24 h watering of the films.
  • the investigations were carried out in accordance with DIN 53504. Table 3: Comparison of Tensile Results for Polyurethane from Organic Solution and Aqueous Dispersion

Abstract

La présente invention concerne l'utilisation de revêtements spéciaux en polyuréthanne-urée, le polyuréthanne-urée étant terminé par une unité copolymère constituée d'oxyde de polyéthylène et d'oxyde de polypropylène.
EP09753633A 2008-05-28 2009-05-19 Revêtements hydrophiles à base de polyuréthanne Withdrawn EP2285858A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008025614A DE102008025614A1 (de) 2008-05-28 2008-05-28 Hydrophile Polyurethanbeschichtungen
PCT/EP2009/003544 WO2009143978A1 (fr) 2008-05-28 2009-05-19 Revêtements hydrophiles à base de polyuréthanne

Publications (1)

Publication Number Publication Date
EP2285858A1 true EP2285858A1 (fr) 2011-02-23

Family

ID=40886651

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09753633A Withdrawn EP2285858A1 (fr) 2008-05-28 2009-05-19 Revêtements hydrophiles à base de polyuréthanne

Country Status (7)

Country Link
US (1) US20110077310A1 (fr)
EP (1) EP2285858A1 (fr)
JP (1) JP5437364B2 (fr)
CN (1) CN102046685B (fr)
DE (1) DE102008025614A1 (fr)
HK (1) HK1157368A1 (fr)
WO (1) WO2009143978A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8719964B2 (en) * 2010-09-16 2014-05-13 O'Neill LLC Thin-wall polymer coated articles and gloves and a method therefor
WO2013030148A1 (fr) * 2011-08-29 2013-03-07 Bayer Intellectual Property Gmbh Polyuréthanes thermoplastiques hydrophiles et utilisation desdits polyuréthanes thermoplastiques hydrophiles dans la technique médicale
JP2017531055A (ja) * 2014-08-01 2017-10-19 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリウレタン水性分散液の製造方法および使用ならびに被覆剤におけるその使用
KR20170066356A (ko) * 2014-09-29 2017-06-14 스미토모 세이카 가부시키가이샤 친수성 도막 형성용 수지 조성물
CN107108830B (zh) * 2014-12-26 2020-02-11 旭化成株式会社 多异氰酸酯组合物及其制造方法、封端多异氰酸酯组合物及其制造方法、树脂组合物、以及固化物
CN107949611A (zh) * 2015-10-30 2018-04-20 三洋化成工业株式会社 溶剂系印刷油墨用粘合剂和使用其的溶剂系印刷油墨
EP3424973A1 (fr) * 2017-07-04 2019-01-09 Covestro Deutschland AG Un article contenant un polyuréthanne thermoplastique expansé et un revêtement
EP3424974A1 (fr) * 2017-07-04 2019-01-09 Covestro Deutschland AG Un article contenant un polyuréthanne thermoplastique expansé et un revêtement à base d'eau

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2221798C3 (de) * 1972-05-04 1978-07-06 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Polyurethanharnstoff-Lösungen
DE2252280C3 (de) 1972-10-25 1981-03-19 Bayer Ag, 5090 Leverkusen Textilbeschichtungen und Syntheseleder aus Polycarbonat-Polyharnstoff-Elastomeren
DE3313239A1 (de) 1983-04-13 1984-10-18 Bayer Ag, 5090 Leverkusen Verfahren zur mehrstrichigen umkehrbeschichtung mit polyurethanloesungen
DE3836030A1 (de) * 1988-10-22 1990-05-03 Bayer Ag Pur-dispersionen und loesemittel enthaltende beschichtungsmassen und deren verwendung zur herstellung von wasserdampfdurchlaessigen pur-beschichtungen
US5041100A (en) * 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US5061424A (en) * 1991-01-22 1991-10-29 Becton, Dickinson And Company Method for applying a lubricious coating to an article
US5589563A (en) 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
JPH08253547A (ja) * 1995-03-16 1996-10-01 Asahi Glass Co Ltd ポリウレタン溶液組成物
EP0920467A4 (fr) * 1996-08-26 1999-10-13 Tyndale Plains Hunter Ltd Polyether-polyurethannes hydrophiles et hydrophobes et utilisations correspondantes
JP2873368B2 (ja) * 1996-12-12 1999-03-24 三洋化成工業株式会社 紙塗工用塗料組成物およびそれを用いた塗工紙
US6221425B1 (en) * 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
DE19914882A1 (de) * 1999-04-01 2000-10-05 Bayer Ag Selbstvernetzende Polyurethan-, Polyurethan-Polyharnstoff- bzw. Polyharnstoff-Dispersionen für Schlichten
US6716895B1 (en) * 1999-12-15 2004-04-06 C.R. Bard, Inc. Polymer compositions containing colloids of silver salts
DE10122444A1 (de) * 2001-05-09 2002-11-14 Bayer Ag Polyurethan-Polyharnstoff Dispersionen als Beschichtungsmittel
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
JP4381742B2 (ja) * 2002-08-01 2009-12-09 セントラル硝子株式会社 防曇性膜及びその形成方法並びに防曇性膜形成用塗布剤
WO2004064770A2 (fr) * 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Utilisation d'un inhibiteur de smad3 dans le traitement d'une fibrose dependant de la transition epithelium-mesenchyme comme dans l'oeil et le rein
US20050054774A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coating
DE102004002525A1 (de) * 2004-01-16 2005-08-04 Bayer Materialscience Ag Beschichtungsmittelzusammensetzung
DE102004060139A1 (de) * 2004-12-13 2006-06-29 Bayer Materialscience Ag Festkörperreiche Polyurethanpolyharnstoff-Dispersionen
TWI388584B (zh) * 2005-03-04 2013-03-11 Showa Denko Kk The film is formed with a paste
US20060212106A1 (en) * 2005-03-21 2006-09-21 Jan Weber Coatings for use on medical devices
DE102006002156A1 (de) * 2006-01-17 2007-07-19 Bayer Materialscience Ag Polyurethan-Polyharnstoff-Dispersionen auf Basis von Polyether-Polycarbonat-Polyolen
DE102006009928A1 (de) * 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102006016639A1 (de) * 2006-04-08 2007-10-11 Bayer Materialscience Ag Verfahren zur Herstellung von Polyurethan-Schäumen
EP2103318A1 (fr) * 2008-03-20 2009-09-23 Bayer MaterialScience AG Appareils médicaux dotés de couches hydrophiles
EP2103317A1 (fr) * 2008-03-20 2009-09-23 Bayer MaterialScience AG Appareils médicaux dotés de couches hydrophiles
EP2103316A1 (fr) * 2008-03-20 2009-09-23 Bayer MaterialScience AG Dispersions de polyuréthane hydrophiles
EP2108386A1 (fr) * 2008-04-08 2009-10-14 Bayer MaterialScience AG Appareils médicaux dotés d'un revêtement de polyuréthane antimicrobien
EP2108383A1 (fr) * 2008-04-08 2009-10-14 Bayer MaterialScience AG Appareils médicaux dotés d'un revêtement de polyuréthane-urée antimicrobien
US20110160310A1 (en) * 2008-09-04 2011-06-30 Bayer Materialscience Ag Tcb based hydrophilic polyurethane dispersions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009143978A1 *

Also Published As

Publication number Publication date
CN102046685A (zh) 2011-05-04
JP2011523962A (ja) 2011-08-25
WO2009143978A1 (fr) 2009-12-03
US20110077310A1 (en) 2011-03-31
DE102008025614A1 (de) 2009-12-03
JP5437364B2 (ja) 2014-03-12
HK1157368A1 (en) 2012-06-29
CN102046685B (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
EP2331156B1 (fr) Solutions de polyuréthane hydrophiles à base de tcd
EP2265296B1 (fr) Appareils médicaux dotés de revêtements hydrophiles
EP2265294B1 (fr) Instruments médicaux comportant des revêtements hydrophiles
EP2265295B1 (fr) Dispersions de polyurethane hydrophiles
EP2478028B1 (fr) Dispersions d'urées de polyuréthane hydrophiles
EP2257581B1 (fr) Solutions de polyuréthane hydrophiles
EP2331596B1 (fr) Dispersions de polyuréthane hydrophiles à base de tcd
EP2285855A1 (fr) Revêtements hydrophiles à base de polyuréthanne
EP2108386A1 (fr) Appareils médicaux dotés d'un revêtement de polyuréthane antimicrobien
EP2285858A1 (fr) Revêtements hydrophiles à base de polyuréthanne
EP2478026B1 (fr) Urées de polyuréthane hydrophiles à base de cyclo-hexane-di-méthanol
EP2108385A1 (fr) Solution de polyuréthane-urée contenant de l'argent
EP2478027B1 (fr) Solutions de polyuréthane hydrophiles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20110801

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110816

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COVESTRO DEUTSCHLAND AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171201